Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review

Laurie, Scott A.; Ho, Alan L.; Fury, Matthew G.; Sherman, Eric J.; Pfister, David G.

doi:10.1016/s1470-2045(10)70245-x

Cited by 329 publications

(268 citation statements)

References 47 publications

Supporting

Mentioning

260

Contrasting

Unclassified

Order By: Relevance

“…The counterpart of a less aggressive surgical tumor resection, is applying radiotherapy on microscopic close or positive margins without gaining any additional chances to prevent relapses. Unfortunately, classical chemotherapies have not proved effective in ACC so far; and since chemotherapy appears to be ineffective against most salivary gland ACCs, testing a patient's tumor for sensitivity to a chemotherapy agent before giving it is recommended thus there are no convincing data supporting its routine use, except for metastatic disease [31,32].…”

Section: Discussionmentioning

confidence: 99%

Parotid adenoid cystic carcinoma: Retrospective single institute analysis

Mannelli

Cecconi

Fasolati

et al. 2017

American Journal of Otolaryngology

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oArticle history: Received 10 February 2017 Available online xxxx Purpose: Adenoid cystic carcinoma (ACC) is a uncommon salivary malignant tumor. Our aim was to review our experience with parotid ACC, to identify clinical-pathological parameters predictive for outcome. Materials and methods: We retrospectively reviewed 228 patients affected by parotid gland carcinomas surgically treated at our Institution. Forty-four ACC were included in this study. Multivariate analysis risk models were built to predict recurrence free probability (RFP), distant recurrence free probability (DRFP), overall survival (OS) and disease free survival (DFS). Results: Twenty-one patients (47.7%) died from ACC and 2.3% for other causes. The 41% presented local-regional recurrence, with a regional-RFP rate of 93%, and the 34% reported distant metastases (DM). The five and ten-year OS rates were 74% and 50%, respectively. Conclusions: Recurrences were mainly influenced by the presence of perineural invasion and nerve paralysis, whilst female gender and age b 50 were predictors for good prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Parotid adenoid cystic carcinoma: Retrospective single institute analysis

Mannelli

Cecconi

Fasolati

et al. 2017

American Journal of Otolaryngology

View full text Add to dashboard Cite

show abstract

“…Data from a recently published meta-analysis reported activity for a platinum-and/or doxorubicin-based regimen. 7 Imatinib and EGFR inhibitors have been recently evaluated in this disease with limited success. [8][9][10][11] There is no standard approach for patients who progress to conventional treatments., and thus, enrollment onto clinical trials with novel agents is an accepted approach.…”

Section: Discussionmentioning

confidence: 99%

Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft

Morelli

Calvo

Ordonez

et al. 2012

JCO

View full text Add to dashboard Cite

A 29-year-old woman with a history of advanced adenoid cystic carcinoma (ACC) that was resistant to standard of care treatments presented to our phase I clinic seeking treatment with experimental therapeutics. The patient was diagnosed with ACC 11 years before presentation and had been treated with surgery, radiation therapy, and several lines of conventional treatments including platinums, antracyclines, and imatinib mesylate. Eleven months before being seen in our clinic, the patient had developed a brain metastasis that had been surgically resected. A personalized tumorgraft was successfully established from this lesion by the implantation of fragments of tumor materials in immunecompromised mice as described by our group. 1At the time of presentation, the patient had pulmonary and liver metastasis and, compared with a computed tomography (CT) scan performed 6 months before, was progressing with the growth of a preexisting liver metastasis (Fig 1, before baseline CT scan, black arrow) and development of a new liver lesion, as depicted in Figure 1 (upper panel). Brain magnetic resonance imaging showed a stable 2-mm brain lesion (Fig 1, lower panel, black arrows). The patient was asymptomaticwithEasternCooperativeOncologyGroupperformancestatusof 0 and normal liver, bone marrow, and kidney functions.To determine which phase I clinical studies could be more appropriate for the patient, we characterized her tumor for KRAS mutations and HER2 amplification and found the tumor to be KRAS wild type and not HER2 amplified, respectively (Table 1). Because the patient had a personalized tumorgraft model developed from her brain metastases, we used the model to evaluate a battery of anticancer agents, both conventional and experimental. Briefly, a tumor specimen obtained at the time of removal of her brain tumor had been transplanted and propagated in nude mice. Once the tumor specimen was in an exponential growth phase, cohorts of mice with tumor sizes of 0.15 to 0.3 mL were randomized to several treatment groups. The results of these studies are listed in Figure 2A

show abstract

“…A French literature review examining various chemotherapy regimens for ACC based on studies published after 2000 suggested that the strongest rationale remains in favor of cisplatin,64 but prospective data is lacking. In addition, a meta‐analysis of published trials concluded that combination chemotherapy offered no advantage over single‐agent therapy 60. In view of these observations, the role of single‐agent or combination chemotherapy for palliation of ACC remains controversial.…”

Section: Introductionmentioning

confidence: 99%

Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials

Chakraborty²,

et al. 2015

View full text Add to dashboard Cite

BackgroundAdenoid cystic carcinoma (ACC) is a rare tumor of secretory glands. In this study, recent advances in molecular characterization and in therapeutics are reviewed.MethodsA search of articles in PubMed and of abstracts from national meetings was performed regarding ACC.ResultsRecent genetic analyses found that recurrent chromosome 6:9 translocations in ACC generate an MYB:NFIB gene fusion resulting in overexpression of the MYB oncoprotein. Several other frequent mutations are recently published that may be relevant for drug development. Several trials of targeted drugs are reviewed. Some agents delay tumor progression, but tumor responses remain rare.ConclusionACCs have a characteristic chromosomal translocation, but also frequently pick up additional mutations. Clinical research is limited by the rarity and slow growth of ACC. Several ongoing trials are testing agents that inhibit fibroblast growth factor receptor signaling or other signaling pathways. Novel treatments based on the recently sequenced tumor genome are under development. © 2015 The Authors Head & Neck Published by Wiley Periodicals, Inc. 38: 620–627, 2016

show abstract

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review

Cited by 329 publications

References 47 publications

Parotid adenoid cystic carcinoma: Retrospective single institute analysis

Parotid adenoid cystic carcinoma: Retrospective single institute analysis

Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft

Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials

Contact Info

Product

Resources

About